Lonza Capacity Update June 2023: Small Molecule

The increasing complexity of small molecules in the development pipeline has put pressure on CDMOs like Lonza to keep up with the requirements of pharma and biotech companies. For example, many small molecules are challenging to develop with multiple chemical steps involved, and APIs deemed highly potent are becoming increasingly common. We have invested in our integrated services to ensure we are able to support customers all the way through the development pipeline, from milligram to tonne scale. In particular, we have invested heavily in API support for early phase development at our site in Nansha, China, including support for HPAPIs.

In this presentation from the June 2023 Outsourced Pharma Capacity Update, examine the potential pitfalls in early development and how our capabilities at Lonza Small Molecules help customers avoid them.